Selecting a biotech contract manufacturer (CDMO) late in the development phase has its pros and cons. It’s essential to carefully consider these factors to make the best decision for your company.
Pros of selecting a CDMO late in the development phase:
Well-defined project scope: By waiting until later in the development process, your project scope and requirements are more likely to be well-defined and stable. This can make it easier to identify the most suitable CDMO for your specific needs and ensure a more efficient collaboration for your life science or IVD manufacturing.
Financial flexibility: Delaying the engagement of a CDMO can provide financial flexibility, particularly for startups or smaller companies with limited resources. By focusing on other aspects of the business, such as research and development, you can allocate resources more effectively.
Evaluation time: Selecting a CDMO late in the development phase allows for more time to evaluate different CDMOs and make an informed decision based on your unique life science or IVD manufacturing requirements.
Cons of selecting a CDMO late in the development phase:
Missed opportunities for collaboration: By engaging a CDMO later in the development process, you might miss out on valuable opportunities for collaboration and input from their specialized expertise. This can impact the overall efficiency and effectiveness of your product development.
Tech transfer challenges: Engaging a CDMO late in the development process can lead to a more complicated and time-consuming tech transfer, as the CDMO may need more time to understand and adapt to your processes and requirements.
Longer time to market: Delaying the engagement of a CDMO can result in a longer time to market, as the transition from development to scale-up and manufacturing may be more challenging and time-consuming.
Resource planning difficulties: Engaging a CDMO late in the development process can make it more difficult to plan and allocate resources effectively, potentially leading to delays or budget overruns.
In summary
While there are some benefits to selecting a biotech contract manufacturer late in the development phase, the potential drawbacks can have a significant impact on your product’s success. Engaging a reputable CDMO like Argonaut early in the development process can provide valuable collaboration opportunities, streamline tech transfer, and help ensure a more efficient and successful product development and life science or IVD manufacturing process. It’s essential to carefully weigh the pros and cons based on your specific needs and resources before deciding when to engage a CDMO.
For a deeper look into Early Development vs Late Development vs Post Production, please read the case study: When is the Right Time to Select a Biotech Contract Manufacturer (CMO)? The study also discusses if it is possible to engage a CDMO too early.